Skip to content

A prospective,multicenter ,single set target values study of the MRI-Guided Laser Interstitial Thermal Therapy (MRgLITT) in intracranial malignant tumors

A prospective,multicenter ,single set target values study of the MRI-Guided Laser Interstitial Thermal Therapy (MRgLITT) in intracranial malignant tumors

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300076495
Enrollment
Unknown
Registered
2023-10-10
Start date
2023-10-11
Completion date
Unknown
Last updated
2023-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intracranial malignant tumor

Interventions

Test group:Laser ablation

Sponsors

Huashan Hospital Affiliated to Fudan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: (1) 18 years old =80 years old; (2) Previously diagnosed or newly diagnosed intracranial malignant tumors, such as brain glioma and brain metastases; (3) Lesions could be identified in enhanced MRI images, with the number of lesions =4 and the diameter of a single lesion =3.0cm; (4) There is no indication for craniotomy surgery or craniotomy surgery may cause serious postoperative complications; (5) KPS score =60; (6) Informed consent to the test before the test, and voluntarily sign a written informed consent.

Exclusion criteria

Exclusion criteria: Exclusion criteria: (1) MRI contraindicated patients; (2) The expected survival time is less than 6 months; (3) serious coagulation dysfunction; (4) Evidence of severe or uncontrolled systemic disease; (5) Women who are pregnant or breastfeeding, or women or men who wish to give birth within 6 months; (6) mental abnormality, unable to cooperate with the examination; (7) Participants had participated in other medical device clinical trials one month before screening; Have participated in drug clinical trials within 3 months before the screening period; (8) Any other conditions deemed unsuitable for participation in this trial by the investigator, such as non-malignant tumors, systemic metastases that seriously affect survival, etc.

Design outcomes

Primary

MeasureTime frame
Effective rate of target lesion ablation;

Secondary

MeasureTime frame
Total ablation rate of target lesion;Ablation success rate;Ablation time;KPS score;Software planning under the optical fiber placement once in place success rate;Local control rate of target lesions;NIHSS score;Instrument use satisfaction evaluation;Postoperative complication;Vital signs: temperature, pulse, respiration, blood pressure;Laboratory examination;Equipment failure rate;Incidence of adverse events and serious adverse events;

Countries

China

Contacts

Public ContactMao Ying

Huashan Hospital Affiliated to Fudan University

maoying@fudan.edu.cn+86 138 0176 9152

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026